Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24174506 | 0.77 | LIPG (0.43) | LPLLIPGROCK1F2F11 | |
| SCHEMBL22290338 | 0.75 | LIPG (0.43) | LPLLIPGROCK1EGFRIRAK4 | |
| SCHEMBL30404611 | 0.75 | LIPG (0.46) | LPLLIPGROCK1EGFRIRAK4 | |
| SCHEMBL24175626 | 0.75 | LIPG (0.46) | LPLLIPGROCK1EGFRIRAK4 | |
| SCHEMBL29933385 | 0.72 | LIPG (0.46) | LPLLIPGROCK1F11IRAK4 | |
| SCHEMBL28843389 | 0.72 | LIPG (0.46) | LPLLIPGROCK1F11IRAK4 | |
| SCHEMBL5892571 | 0.71 | LPL (0.44) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL29777947 | 0.71 | LPL (0.44) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL1476213 | 0.70 | LIPG (0.59) | LPLLIPGF11EGFRIRAK4 | |
| SCHEMBL25351139 | 0.69 | LMNA (0.48) | LPLLIPGROCK1F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | LPL 1522/4885LIPG 2840/4885ROCK1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.